HASSELT, Belgium, March 31, 2021 /PRNewswire/ -- Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces the publication in Science Advances of ...

Belgian firm Complix won a €1.9 million grant (about $2.5 million) from the Flanders government’s IWT (Agency for Innovation by Science and Technology in Flanders) to support development of its ...

Firm hopes novel class of single-chain proteins will address targets intractable to antibodies. Young Belgium-based biopharmaceutical company Complix raised €5 million (about $6.10 million) in a ...

Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announced it has ...

Complix has announced that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in ...

Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a unique class of protein therapeutics active against intracellular disease targets, announces the ...

HASSELT, Belgium, March 10, 2021 /PRNewswire/ -- Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant drug ...

Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).

LONDON – Complix NV is in the thick of a €15 million to €20 million (US$19 million to $25 million) Series B fundraising, as it prepares to move the first of its intracellular-targeting Alphabodies ...

Complix is developing Cell Penetrating Alphabodies (CPABs) that can address disease targets present in the cytosol or in the nucleus of human cells. CPABs act with great specificity and high affinity ...